|
Malignant neoplasm of breast
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.
|
25940428 |
2016 |
|
Malignant neoplasm of breast
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The KRAS variant might be a genetic marker for development of triple-negative breast cancer in premenopausal women, and altered gene and miRNA expression signatures should enable molecular and biological stratification of patients with this subgroup of breast cancer.
|
21435948 |
2011 |
|
Malignant neoplasm of breast
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
IR-induced YB-1 phosphorylation in K-RAS wild-type (K-RASwt) and K-RAS-mutated (K-RASmt) breast cancer cell lines was investigated.
|
21392397 |
2011 |
|
Malignant neoplasm of breast
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Discordant cellular response to presurgical letrozole in bilateral synchronous ER+ breast cancers with a KRAS mutation or FGFR1 gene amplification.
|
22879364 |
2012 |
|
Malignant neoplasm of breast
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We report that mutations in both PIK3CA and KRAS are required for the greatest aspirin sensitivity in breast cancer, and that the GSK3β protein was hyperphosphorylated in aspirin-treated double knockin cells, but not in other clones/treatments.
|
26915040 |
2016 |
|
Malignant neoplasm of breast
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In this same cohort, the KRAS-variant did not appear to modify breast cancer risk for BRCA1 carriers.
|
20676756 |
2011 |
|
Malignant neoplasm of breast
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We observed no statistically significant association between BC risk and the let-7a KRAS rs712 polymorphism (GT vs GG, OR = 0.98, 95%CI = 0.66-1.46; TT vs GG, OR = 0.78, 95%CI = 0.28-2.21).
|
26681038 |
2015 |
|
Malignant neoplasm of breast
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We used a high-throughput mass-spectrometric based cancer gene mutation profiling platform to detect 22 mutations of the PIK3CA, AKT1, BRAF, EGFR, HRAS, and KRAS genes in 120 Chinese women with breast cancer.
|
23317280 |
2012 |
|
Malignant neoplasm of breast
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In addition, we show that YAP<sup>S127A</sup>-transduction of the human MDA-MB-231 breast cancer cell line (that carry a similar KRAS mutation) enhances their metastatic activity in vivo.
|
31772328 |
2020 |
|
Malignant neoplasm of breast
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We examined the expression of β III-tubulin, thymidylate synthase, breast cancer susceptibility gene 1 and ribonucleotide reductase M1 (RRM1); identified mutations in epidermal growth factor receptor (EGFR), KRAS, BRAF and HER2; and detected ALK, ROS1 and RET rearrangements.
|
25257380 |
2015 |
|
Malignant neoplasm of breast
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
KRAS G12D point mutation plays an important role in the incidence of non-small-cell lung cancer (NSCLC) as well as colorectal cancer, pancreatic cancer and breast cancer.
|
30876538 |
2019 |
|
Malignant neoplasm of breast
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncology molecular testing: BRAF V600E for vemurafenib in melanoma; EML4-ALK for crizotinib and EGFR for erlotinib and gefitinib in non-small-cell lung cancer; KRAS against the use of cetuximab and panitumumab in colorectal cancer; ERBB2 (HER2/neu) for trastuzumab in breast cancer; BCR-ABL for tyrosine kinase inhibitors in chronic myeloid leukemia; and PML/RARα for all-trans-retinoic acid and arsenic trioxide treatment for acute promyelocytic leukemia.
|
22845480 |
2012 |
|
Malignant neoplasm of breast
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
AKT1, KRAS and PIK3CA mutations and PTEN loss all exist in women with breast cancer in the mainland China.
|
25816324 |
2015 |
|
Malignant neoplasm of breast
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
KRAS mutation testing opened up a new era in routine pathological diagnostics of colorectal cancer similar to the introduction of HER-2 testing in breast cancer with the significant difference that mutational analysis exclusively relies on molecular methodologies.
|
20718705 |
2010 |
|
Malignant neoplasm of breast
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Associations between the KRAS genotype and breast cancer or breast tumor characteristics were assessed using chi-square test and logistic regression models.
|
22436609 |
2012 |
|
Malignant neoplasm of breast
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Finally, hormone replacement therapy (HRT) discontinuation in KRAS-variant patients was associated with a diagnosis of triple negative BC (P < 0.001).
|
25961464 |
2015 |
|
Malignant neoplasm of breast
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The putative presence of a mutation in codon 12 of the K-ras gene was investigated in the endometrium of tamoxifen (TAM) and toremifene (TOR)-treated breast cancer patients.
|
15756272 |
2005 |
|
Malignant neoplasm of breast
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In this study, both EGFR and KRAS mutations were present rarely in this cohort of samples with breast cancer.
|
22386733 |
2012 |
|
Malignant neoplasm of breast
|
0.700 |
Biomarker
|
disease |
BEFREE |
In addition, we provide evidence that KRAS is a target of miR-30c, and that this miRNA suppresses breast cancer cell growth potentially through inhibition of KRAS signaling.
|
22701724 |
2012 |
|
Malignant neoplasm of breast
|
0.700 |
Biomarker
|
disease |
BEFREE |
Our findings provide clues regarding the role of miR-200c as a tumor suppressor in breast cancer through the inhibition of KRAS translation both in vitro and in vivo. miR-200c could be a potential therapeutic target in breast cancer.
|
26392416 |
2015 |
|
Malignant neoplasm of breast
|
0.700 |
Biomarker
|
disease |
BEFREE |
The present study was conducted to test the hypothesis that K-RAS activation is involved in breast cancer risk of south Indian population.
|
25921169 |
2015 |
|
Malignant neoplasm of breast
|
0.700 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Malignant neoplasm of breast
|
0.700 |
Biomarker
|
disease |
BEFREE |
Taken together, this study demonstrates that KRAS is a critical regulator for the metastatic behavior associated with mesenchymal features of breast cancer cells, implicating a novel therapeutic target for basal-type breast cancer.
|
25633745 |
2015 |
|
Malignant neoplasm of breast
|
0.700 |
Biomarker
|
disease |
BEFREE |
The genes of MTUS1, CD44, CCNB1, CCND2 and KRAS with specific SNP loci may be used as biomarkers for diagnosis of breast cancer.
|
25408372 |
2015 |
|
Malignant neoplasm of breast
|
0.700 |
Biomarker
|
disease |
BEFREE |
We aimed to evaluate whether the hormone receptor expression, HER2 and MYC genes and their protein status, and KRAS codon 12 mutations may be prognostic or predictive biomarkers of breast cancer.
|
23555992 |
2013 |